Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX

Haemophilia

Volumn 17, Issue 4, 2011, Pages 579-589

  Valentino, L A ^a   Cooper, D L ^b   Goldstein, B ^b,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NOVO NORDISK INC   (United States)

^c MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

Dental; Inhibitors; Operative haemostasis; Orthopaedic; RFVIIa; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; HEMARTHROSIS; HEMATOMA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; THROMBOSIS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIIA; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; INFANT; MALE; MIDDLE AGED; PERIOPERATIVE CARE; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 79959522825     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02460.x     Document Type: Review

References (60)

1. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life in hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
2. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophiliac patients with inhibitors. Haemophilia 2006; 12: 154-62.
3. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
4. Jiménez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Fernandez I, Hernandez-Navarro F. Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors. Semin Hematol 2008; 45: S64-7.
5. Nilsson IM, Berntorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 56-9.
6. Hay CR, Lozier JN, Lee CA et al. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects. Semin Hematol 1994; 31: 20-5.
7. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations. Semin Hematol 1994; 31: 49-52.
8. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery 890. Thromb Haemost 1998; 80: 773-8.
9. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-32.
10. Biron-Andreani C, Dupeyron G, Mainemer M, Schved JF. Successful use of recombinant factor VIIa in a haemophiliac with inhibitor undergoing cataract surgery. Blood Coagul Fibrinolysis 2001; 12: 215-6.
11. Carr ME, Loughran TP, Cardea JA, Smith WK, Kuhn JG, Dottore MV. Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor. Int J Hematol 2002; 75: 95-9.
12. Chuansumrit A, Sri-Udomporn N, Srimuninnimit V, Juntarukha R. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors. Haemophilia 2001; 7: 532-4.
13. Divanon F, Hecquard C, Borel-Derlon A. Experience with use of recombinant activated factor VII. J Clin Pharm Ther 2002; 27: 133-8.
14. Faradji A, Bonnomet F, Lecocq J et al. Knee joint arthroplasty in a patient with haemophilia A and high inhibitor titre using recombinant factor VIIa (NovoSeven((R))): a new case report and review of the literature. Haemophilia 2001; 7: 321-6.
15. Goddard N. Case studies: orthopaedic surgery in adult patients with haemophilia A with inhibitors. Haemophilia 2005; 11(Suppl 1): 32-7.
16. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis 1991; 21: 1-4.
17. Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
18. Ingerslev J, Feldstedt M, Sindet-Pedersen S. Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII. Lancet 1991; 338: 831-2.
19. Ingerslev J, Holm M, Christiansen K, Knudsen L, Negrier C. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S129-34.
20. Janic D, Brdar R, Kristic Z et al. Successful concurrent triple surgery in an adolescent patient with haemophilia A and inhibitors treated with recombinant factor VIIa. Haemophilia 2007; 13: 214-6.
21. Kanyike FB, Abdul-Salam SA, Prakash B, Sharhan A, Wahib N, Youssef AH. Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait. Haemophilia 1999; 5: 273-5.
22. Konkle BA, Nelson C, Forsyth A, Hume E. Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors. Haemophilia 2002; 8: 706-10.
23. Koyama T, Nagao T, Tsunozaki H, Arai M, Miura O. Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma anad administration of recombinant factor VIII and activated factor VII. Pathophysiol Haemost Thromb 2006; 35: 405-7.
24. Laguna P, Klukowska A. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor. Haemophilia 2005; 11: 2-4.
25. Leblebisatan G, Sasmaz I, Antmen B, Kilinc Y, Sizmaz S, Yagmur M. A successful use of recombinant factor VIIa in a patient with inhibitors, for bilateral cataract operation and circumcision. Haemophilia 2006; 12: 187-9.
26. Leebeek FW, Kappers-Klunne MC, Jie KS. Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII. Haemophilia 2004; 10: 250-3.
27. Lorenzo JI, Montoro JM, Aznar JA. Postoperative use of rFVIIa by continuous infusion in a haemophilic boy. Haemophilia 1999; 5: 135-8.
28. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
29. Mauser-Bunschoten EP, Goede-Bolder A, Wielenga JJ, Levi M, Peerlinck K. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. Neth J Med 1998; 53: 249-55.
30. Mauser-Bunschoten EP, Goede-Bolder AD, Leebeek FW et al. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia 2002; 8: 649-56.
31. Mehta S, Nelson CL, Konkle BA, Vannozzi B. Total knee arthroplasty using recombinant factor VII in hemophilia-A patients with inhibitors. A report of three cases. J Bone Joint Surg Am 2004; 86-A: 2519-21.
32. Menart C, Cognet V, Petit PY, Massignon D, Negrier C. Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of Novoseven. Blood Coagul Fibrinolysis 1998; 9: 289-90.
33. Montoro JB, Altisent C, Pico M, Cabanas MJ, Vila M, Puig LL. Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. Haemophilia 1998; 4: 762-5.
34. Morimoto Y, Yoshioka A, Shima M, Kirita T. Intraoral Hemostasis using a recombinant activated factor VII preparation in a hemophilia A patient with inhibitor. J Oral Maxillofac Surg 2003; 61: 1095-7.
35. O'Connell N, McMahon C, Smith J, Khair K, Hann IM, Liesner R. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Br J Haematol 2002; 116: 632-5.
36. O'Connell N, Chen J, Byrne M, O'Shea E, Smyth H, Smith OP. Massive pseudotumour resection with recombinant factor VIIa (NovoSeven) cover. Br J Haematol 2002; 116: 645-8.
37. O'Marcaigh AS, Schmalz BJ, Shaughnessy WJ, Gilchrist GS. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
38. Pekcelen Y, Yavuz AS, Namli S, Gucukoglu A. Short-course use of recombinant factor VIIa in a haemophilia patient with inhibitor undergoing cataract surgeries. Blood Coagul Fibrinolysis 2005; 16: 445-6.
39. Perez R, Sosa R. Sequential treatment with bolus and continuous infusion of recombinant factor VIIa for hip arthroplasty in a patient with haemophilia A and inhibitor. Haemophilia 2002; 8: 822-5.
40. Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E et al. Surgery in haemophilic patients with inhibitor: 20years of experience. Haemophilia 2004; 10(Suppl. 2): 30-40.
41. Rocino A, Carola A, Papa ML et al. Major surgery for a gastric cancer in a haemophilic with high inhibitor titre successfully performed by the use of recombinant FVIIa. Haemophilia 1999; 5: 441-4.
42. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-31.
43. Saba HI, Morelli GA, Azam RR, Klein CJ, Letson GD. Efficacy of NovoSeven(R) during surgery on a haemophiliac with previous history of inhibitors. Haemophilia 2003; 9: 131-6.
44. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
45. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
46. Schmidt ML, Smith HE, Gamerman S, DiMichele D, Glazer S, Scott JP. Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor. Br J Haematol 1991; 78: 460-3.
47. Sheth S, DiMichele D, Lee M et al. Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: Perioperative management using high- dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001; 7: 227-32.
48. Slaoui M, Lambert T, Stieltjes N, Claeyssens S, Borel-Derlon A. Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: a report of five cases. Blood Coagul Fibrinolysis 2004; 15: 687-91.
49. -1 is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 949-53.
50. Smith OP, Hann IM. rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Br J Haematol 1996; 92: 1002-4.
51. Smith OP. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors. Pathophysiol Haemost Thromb 2002; 32(Suppl. 1): 22-5.
52. Solimeno LP, Perfetto OS, Pasta G, Santagostino E. Total joint replacement in patients with inhibitors. Haemophilia 2006; 12(Suppl. 3): 113-6.
53. Tagariello G, De Biasi E, Gajo GB et al. Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases. Haemophilia 2000; 6: 581-3.
54. Tagariello G, Bisson R, Radossi P et al. Concurrent total hip and knee replacements in a patient with haemophilia with inhibitors using recombinant factor VIIa by continuous infusion. Haemophilia 2003; 9: 738-40.
55. Takedani H, Mikami S, Kawasaki N et al. Excision of pseudotumour in a patient with haemophilia A and inhibitor managed with recombinant factor VIIa. Haemophilia 2004; 10: 179-82.
56. Vermylen J, Peerlinck K. Optimal care of inhibitor patients during surgery 271. Eur J Haematol Suppl 1998; 63: 15-7.
57. Warner MN, Metrakos P, Deschenes M, Barkun J, Tchervenkov J, Rivard GE. Orthotopic liver transplantation in a severe hemophilia A patient with factor VIII inhibitors. Blood 2003; 102: 800a.
58. Giangrande PL, Wilde JT, Madan B et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophiliac patients with inhibitors. Haemophilia 2009; 15: 501-8.
59. Takedani H, Kawahara H, Kajiwara M. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa. Haemophilia 2010; 16: 290-5.
60. NovoSeven Prescribing Information. NovoSeven (R) RT [Package Insert]. Denmark: Bagsvaerd, Novo Nordisk A/S, 2008.